Alterity Therapeutics Stock Fundamentals
| ATHE Stock | USD 3.72 0.27 6.77% |
Alterity Therapeutics fundamentals help investors to digest information that contributes to Alterity Therapeutics' financial success or failures. It also enables traders to predict the movement of Alterity Stock. The fundamental analysis module provides a way to measure Alterity Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alterity Therapeutics stock.
At present, Alterity Therapeutics' Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 28.3 M, whereas EBIT is projected to grow to (16.9 M). Alterity | Select Account or Indicator |
Alterity Therapeutics Company Shares Outstanding Analysis
Alterity Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Alterity Therapeutics Shares Outstanding | 8.74 M |
Most of Alterity Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterity Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Alterity Shares Outstanding Historical Pattern
Today, most investors in Alterity Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Alterity Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Alterity Therapeutics shares outstanding as a starting point in their analysis.
Alterity Therapeutics Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Alterity Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
Based on the latest financial disclosure, Alterity Therapeutics has 8.74 M of shares currently outstending. This is 95.16% lower than that of the Biotechnology sector and 91.82% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 98.47% higher than that of the company.
Alterity Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alterity Therapeutics's current stock value. Our valuation model uses many indicators to compare Alterity Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alterity Therapeutics competition to find correlations between indicators driving Alterity Therapeutics's intrinsic value. More Info.Alterity Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Alterity Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Alterity Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Alterity Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterity Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics of similar companies.Alterity Therapeutics is currently under evaluation in shares outstanding category among its peers.
Alterity Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Alterity Therapeutics from analyzing Alterity Therapeutics' financial statements. These drivers represent accounts that assess Alterity Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Alterity Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 47.5M | 31.3M | 17.0M | 18.2M | 21.0M | 19.9M | |
| Enterprise Value | 19.5M | (3.4M) | 1.4M | 5.8M | 6.6M | 6.3M |
Alterity Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alterity Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alterity Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Alterity Fundamentals
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (6.13) % | ||||
| Current Valuation | 24.77 M | ||||
| Shares Outstanding | 8.74 M | ||||
| Shares Owned By Institutions | 1.28 % | ||||
| Number Of Shares Shorted | 148.54 K | ||||
| Price To Earning | (4.84) X | ||||
| Price To Book | 4.36 X | ||||
| Price To Sales | 8.68 X | ||||
| Revenue | 4.02 M | ||||
| Gross Profit | 3.63 M | ||||
| EBITDA | (19.57 M) | ||||
| Net Income | (19.12 M) | ||||
| Cash And Equivalents | 34.81 M | ||||
| Cash Per Share | 0.87 X | ||||
| Total Debt | 159.04 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.07 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (12.61 M) | ||||
| Short Ratio | 1.39 X | ||||
| Earnings Per Share | (6.99) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.68 | ||||
| Market Capitalization | 34.88 M | ||||
| Total Asset | 19.22 M | ||||
| Retained Earnings | (214.16 M) | ||||
| Working Capital | 13.66 M | ||||
| Current Asset | 14.26 M | ||||
| Current Liabilities | 1.73 M | ||||
| Net Asset | 19.22 M |
About Alterity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterity Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 14.4 K | 13.7 K | |
| Total Revenue | 4.6 M | 4.9 M | |
| Cost Of Revenue | 192.9 K | 217.8 K | |
| Stock Based Compensation To Revenue | 0.25 | 0.24 | |
| Sales General And Administrative To Revenue | 1.07 | 1.02 | |
| Research And Ddevelopement To Revenue | 4.17 | 3.97 | |
| Ebit Per Revenue | (5.61) | (5.89) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Alterity Therapeutics Piotroski F Score and Alterity Therapeutics Altman Z Score analysis. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.99) | Revenue Per Share | Quarterly Revenue Growth 0.384 | Return On Assets | Return On Equity |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.